3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma
14
Lymphoma, Large B-Cell, Diffuse
10
Glioblastoma
8
Astrocytoma
6
Multiple Myeloma
5
Lymphoma, Non-Hodgkin
5
Lymphoma, Follicular
5
Lymphoma, Large-Cell, Immunoblastic
4
Glioma
4
Central Nervous System Neoplasms
4
Neoplasms
3
Hodgkin Disease
3
Gliosarcoma
3
Brain Neoplasms
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Lymphoma, Mantle-Cell
2
Leukemia
2
Breast Neoplasms
2
Oligodendroglioma
1
Neutropenia
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell
1
Lymphoma, B-Cell
1
Lymphatic Diseases
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Monocytic, Acute
1
Interventions
Rituximab
2
Epoetin Alfa
2
Early Intervention, Educational
2
Dexamethasone
2
Darbepoetin alfa
2
Bortezomib
2
ponatinib
1
pegaspargase
1
isatuximab
1
ibrutinib
1
ibritumomab tiuxetan
1
ferrous sulfate
1
ferric gluconate
1
ferric carboxymaltose
1
cirmtuzumab
1
blinatumomab
1
asparaginase erwinia chrysanthemi recombinant
1
acalabrutinib
1
Vorinostat
1
Vincristine
1
Sucrose
1
Prednisone
1
Methotrexate
1
Melphalan
1
Lenalidomide
1
Imatinib Mesylate
1
Ifosfamide
1
Etoposide
1
Doxorubicin
1
Daunorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Lymphoproliferative Disorders
×
Carmustine
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts